Oncología médica

2014

1. A new biomarker panel in bronchoalveolar lavage for an improved lung cancer diagnosis

   Journal of Thoracic Oncology, Vol. 9, Núm. 10, pp. 1504-1512

2. Acceptance of portable infusion pumps for chemotherapy in patients with metastatic colorectal cancer

   Atencion Farmaceutica, Vol. 16, Núm. 2, pp. 95-101

3. Bevacizumab in combination with FOLFIRI in the first-line treatment of patients with advanced colorectal cancer: A single-institution experience

   Journal of Analytical Oncology, Vol. 3, Núm. 1, pp. 26-32

4. Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors

   Medical Oncology, Vol. 31, Núm. 1

5. Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: Biological basis and therapeutic strategies

   Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 339-350

6. Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer

   PLoS ONE, Vol. 9, Núm. 10

7. Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).

   British journal of cancer, Vol. 111, Núm. 6, pp. 1060-1064

8. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer

   Oncology Research, Vol. 21, Núm. 4, pp. 181-191

9. Phase lb study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy

   Clinical Cancer Research, Vol. 20, Núm. 7, pp. 1935-1945

10. Prognostic factors for relapse in stage I seminoma: A new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2173-2178

11. Reexcision after inolved margins. A survey to evaluate variability

    Revista de Senologia y Patologia Mamaria, Vol. 27, Núm. 3, pp. 123-130

12. Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 9, pp. 814-822

13. Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base

    Clinical and Translational Oncology, Vol. 16, Núm. 11, pp. 959-965

14. Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes

    Journal of Pathology, Vol. 232, Núm. 1, pp. 32-42

15. Tratamiento médico tras un carcinoma ductal in situ de mama

    Revisiones en Cancer, Vol. 28, Núm. 6, pp. 252-258

16. Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors

    Critical Reviews in Oncology/Hematology, Vol. 89, Núm. 1, pp. 62-72

17. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155

18. VAV3 mediates resistance to breast cancer endocrine therapy

    Breast Cancer Research, Vol. 16, Núm. 3